Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $16.39, up 1.93%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CPRX shares have gain 1.17% over the last week, with a monthly amount glided 17.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 13, March 2024, Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD). In a post published today on Yahoo Finance, AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on March 14, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $27. Previously, BofA Securities started tracking the stock with Buy rating on March 07, 2024, and set its price target to $23. On December 21, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $30 on the stock. ROTH Capital downgraded its rating to a Neutral and increased its price target to $15.50 on August 24, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight. In a note dated October 05, 2016, Piper Jaffray upgraded an Overweight rating on this stock.
Catalyst Pharmaceuticals Inc [CPRX] stock has fluctuated between $11.09 and $18.22 over the past year. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $16.39 at the most recent close of the market. An investor can expect a potential return of 18.24% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 398.20M for the trailing twelve months, which represents a growth of 81.98%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.2 and Total Capital is 0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.02 points at the first support level, and at 15.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.59, and for the 2nd resistance point, it is at 16.79.
Catalyst Pharmaceuticals Inc [CPRX] reported earnings per share of $0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.26/share, meaning a difference of $0.05 and a surprise factor of 19.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.29 per share as compared to estimates of -$0.28 per share, a difference of -$0.01 representing a surprise of -3.60%.
Ratios To Look Out For
For context, Catalyst Pharmaceuticals Inc’s Current Ratio is 2.88. In addition, the Quick Ratio stands at 2.68 and the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 4.85, the price to book ratio is 4.53 and price to earnings (TTM) ratio is 26.90.
Transactions by insiders
Recent insider trading involved Harper Molly, Director, that happened on Dec 15 ’23 when 14000.0 shares were sold. Director, Tierney David S completed a deal on Dec 12 ’23 to sell 50000.0 shares. Meanwhile, VP, Treasurer and CFO GRANDE ALICIA sold 60000.0 shares on Dec 11 ’23.
